Gefitinib

Generic Name: Gefitinib

Brand Names: Iressa, Gefitinib Mylan

Drug Type: Small Molecule

Chemical Formula: C_₂₂H_₂₄ClFN_₄O_₃

CAS Number: 184475-35-2

Unique Ingredient Identifier: S65743JHBS

Background: Gefitinib (originally coded ZD1839) is a drug used in the treatment of certain types of cancer. Acting in a similar manner to erlotinib (marketed as Tarceva), gefitinib selectively targets the mutant proteins in malignant cells. It is marketed by AstraZeneca under the trade name Iressa.

Indication: For the continued treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of either platinum-based or docetaxel chemotherapies.

Associated Conditions: Metastatic Non-Small Cell Lung Cancer

Associated Therapies: -

Clinical Trials

Study Evaluating Gefitinib (IRESSA®) in Subjects With Solid Malignancies That Are Locally Advanced, Recurrent or Metastatic

Phase 1

Completed

Conditions: Tumors

Interventions: Drug: Gefitinib

First Posted Date: 2005-08-09

Last Posted Date: 2009-04-23

Lead Sponsor: AstraZeneca

Target Recruit Count: 66

Registration Number: NCT00127829

Locations: 🇺🇸
Research Site, Palm Springs, California, United States

Gefitinib in Treating Patients Who Are Undergoing Surgery and/or Radiation Therapy for Locally Advanced or Recurrent Squamous Cell Skin Cancer

Phase 2

Completed

Conditions: Recurrent Skin Cancer
Squamous Cell Carcinoma of the Skin

Interventions: Drug: Gefitinib
Radiation: Radiotherapy
Other: laboratory biomarker analysis
Procedure: Conventional surgery

First Posted Date: 2005-08-04

Last Posted Date: 2019-08-30

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 23

Registration Number: NCT00126555

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Gemcitabine, Cisplatin, and Gefitinib in Treating Patients Who Are Undergoing Surgery for Stage III Non-Small Cell Lung Cancer

Phase 2

Completed

Conditions: Lung Cancer

First Posted Date: 2005-02-08

Last Posted Date: 2012-07-16

Lead Sponsor: European Organisation for Research and Treatment of Cancer - EORTC

Registration Number: NCT00103051

Locations: 🇳🇱
Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands

Gefitinib in Treating Patients With Locally Advanced Esophageal Cancer

Phase 2

Completed

Conditions: Esophageal Cancer

Interventions: Drug: gefitinib

First Posted Date: 2005-01-10

Last Posted Date: 2016-12-13

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 70

Registration Number: NCT00100945

Locations: 🇺🇸
BroMenn Regional Medical Center, Normal, Illinois, United States
🇺🇸
Joliet Oncology-Hematology Associates, Limited - West, Joliet, Illinois, United States
🇺🇸
St. Joseph Medical Center, Bloomington, Illinois, United States

and more 116 locations

Gefitinib and Sirolimus in Treating Patients With Recurrent or Refractory Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Phase 1

Withdrawn

Conditions: Lung Cancer

First Posted Date: 2004-12-08

Last Posted Date: 2012-10-04

Lead Sponsor: Jonsson Comprehensive Cancer Center

Registration Number: NCT00098462

Gefitinib and Everolimus in Treating Patients With Stage IIIB or Stage IV or Recurrent Non-Small Cell Lung Cancer

Phase 1

Completed

Conditions: Lung Cancer

Interventions: Drug: everolimus
Drug: gefitinib

First Posted Date: 2004-11-10

Last Posted Date: 2016-01-21

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 74

Registration Number: NCT00096486

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Gefitinib in Treating Patients With Locally Advanced or Metastatic Thyroid Cancer That Did Not Respond to Iodine Therapy

Phase 2

Completed

Conditions: Head and Neck Cancer

Interventions: Drug: Gefitinib

First Posted Date: 2004-11-09

Last Posted Date: 2017-05-31

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 27

Registration Number: NCT00095836

Locations: 🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Oxaliplatin, Gefitinib, and Radiation Therapy in Treating Patients With Locally Advanced or Metastatic Esophageal Cancer

Phase 1

Terminated

Conditions: Esophageal Cancer

First Posted Date: 2004-10-08

Last Posted Date: 2015-10-06

Lead Sponsor: Roswell Park Cancer Institute

Registration Number: NCT00093652

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Gefitinib After Chemotherapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Phase 3

Terminated

Conditions: Lung Cancer

First Posted Date: 2004-09-08

Last Posted Date: 2012-07-16

Lead Sponsor: European Organisation for Research and Treatment of Cancer - EORTC

Target Recruit Count: 598

Registration Number: NCT00091156

Locations: 🇧🇪
Clinique Sainte Elisabeth, Namur, Belgium
🇨🇾
Bank Of Cyprus Oncology Centre, Nicosia, Cyprus
🇪🇬
National Cancer Institute of Egypt, Cairo, Egypt

and more 25 locations

Phase III Trial Of Docetaxel Versus Docetaxel Plus ZD1839 In Head And Neck Cancer

Phase 3

Terminated

Conditions: Metastatic Head and Neck Cancer
Recurrent Head and Neck Cancer

Interventions: Drug: docetaxel
Other: placebo
Drug: gefitinib

First Posted Date: 2004-08-05

Last Posted Date: 2015-05-06

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 270

Registration Number: NCT00088907

Locations: 🇺🇸
Eastern Cooperative Oncology Group, Boston, Massachusetts, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy